News
Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment. Click here to read an ...
This year, drug companies have been living under a cloud of uncertainty created by the Trump administration. Threats of tough ...
Monthly weight-loss shots on the horizon! Learn about new drugs like MariTide and why Black participation in clinical trials ...
Amgen Inc. (NASDAQ:AMGN) ranks among the best set-it-and-forget-it stocks to buy. On June 24, Piper Sandler reaffirmed its ...
Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 23, the company ...
Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...
Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round.
Amgen's MariTide showed strong weight loss and metabolic gains in Phase 2, with no new safety signals as Phase 3 trials begin in obesity and T2D.
Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an eight-week period.
Truist continues to credit MariTide with potential peak sales of $5.6 billion, acknowledging Amgen’s historical strength in drug commercialization, but expressed concerns about the treatment’s ...
Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like vomiting, according to mid-stage trial results presented at a medical ...
Amgen will host a webcast call for the investment community in conjunction with the ADA Scientific Sessions. On Monday, June 23 at 4:30 p.m. CDT, Jay Bradner, M.D., executive vice president of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results